Elena Caremoli-Rota
Bergamo, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Journal: The New England journal of medicine
Published: January 15, 2025
Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence.
Journal: Critical reviews in oncology/hematology
Published: January 13, 2023
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Journal: The New England journal of medicine
Published: December 06, 2018
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Journal: The Lancet. Oncology
Published: November 14, 2017
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.
Journal: World journal of gastroenterology
Published: January 20, 2017
Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials.
Journal: Clinical breast cancer
Published: October 12, 2016
Tivantinib: critical review with a focus on hepatocellular carcinoma.
Journal: Expert opinion on investigational drugs
Published: October 14, 2014
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: February 19, 2014
Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.
Journal: Future oncology (London, England)
Published: February 05, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026